Tag: Poxel
Poxel postpones its publication until the end of April
By Alexandra Saintpierre Published on 03/28/2024 at 8:26 p.m. Photo credit © Poxel (Boursier.com) — The biopharmaceutical company Poxel will publish its 2023…
Poxel will publish its 2023 annual results by the end of April 2024 – 03/28/2024 at 6:00 p.m.
LYON, France, March 28, 2024 – POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH)…
Poxel postpones the publication of its results until the end of April
(AOF) – Poxel announces the publication of its 2023 annual results “at the end of April 2024” when it was initially scheduled for April 9. The biotech specialist in serious…
Poxel postpones the publication of its results until the end of April – 03/28/2024 at 6:18 p.m.
(AOF) – Poxel announces the publication of its 2023 annual results “at the end of April 2024” when it was initially scheduled for April 9. The biotech specialist in serious…
Poxel: visibility until March 2024, “significant” reduction in workforce
(AOF) – Poxel “remains focused on seeking additional funding in order to execute its strategic plan in rare diseases”. The biotech specialist in innovative treatments against serious chronic diseases with…
Poxel provides an update on its activities – 12/21/2023 at 6:15 p.m.
• The Company remains focused on seeking additional funding to execute its strategic plan in rare diseases• Exclusive discussions with a leading investor to monetize royalties from sales of TWYMEEG®…
Poxel: cash flow of 5.3 million euros, visibility until mid-2025 – 08/11/2023 at 6:25 p.m.
(AOF) – Poxel announces that as of September 30, 2023, its cash and cash equivalents amounted to 5.3 million euros. The biotech specialist in innovative treatments against metabolic diseases, including…
Poxel: cash flow of 5.3 million euros, visibility until mid-2025
(AOF) – Poxel announces that as of September 30, 2023, its cash and cash equivalents amounted to 5.3 million euros. The biotech specialist in innovative treatments against metabolic diseases, including…
Poxel announces its upcoming participation in a scientific conference
By Hector Chaunu Published on 02/10/2023 at 6:03 p.m. Photo credit © Poxel (Boursier.com) — Poxel SA, a…
Poxel announces presentation on rare diseases
(AOF) – Poxel today announces its participation in the 12th International Meeting on AMPK, on October 4. Sophie Bozec, Executive Vice President, Pharmacology & Scientific Communication, will give a virtual…
Poxel: net loss doubled in H1
By Arnaud Bivès Published on 09/26/2023 at 08:01 a.m. Photo credit © Poxel (Boursier.com) — The net result…
Poxel: Losses widen, the stock drops
Read also (CercleFinance.com) – Poxel fell sharply on Tuesday on the Paris Stock Exchange after announcing in the morning a near doubling of its losses during the first half. Around…